SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 2-YEAR EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, FUTURE 1

Kavanaugh A, Mease P, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Mpofu S (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 75

Pages Range: 598-598

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

UC San Diego School of Medicine US United States (USA) (US) Novartis AG CH Switzerland (CH) Barts Health NHS Trust GB United Kingdom (GB) Swedish Medical Center US United States (USA) (US) Monash University AU Australia (AU) Dallas VA Medical Center US United States (USA) (US) Hasselt University / Universiteit Hasselt BE Belgium (BE)

How to cite

APA:

Kavanaugh, A., Mease, P., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2016). SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 2-YEAR EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, FUTURE 1. (pp. 598-598).

MLA:

Kavanaugh, A., et al. "SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 2-YEAR EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, FUTURE 1." 2016. 598-598.

BibTeX: Download